跳至主要内容
临床试验/NCT02493140
NCT02493140Unknown不适用

Evaluation of Efficacy and Safety of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers: a Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial

Dialpha1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2015年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
66
试验地点
1
主要终点
Body weight reduction

研究概览

简要总结

The purpose of this study is to assess the efficacy and safety of a cashew apple extract on weight management and associated metabolic risk factors in overweight/obese volunteers, versus placebo, after 12 weeks of treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •27 ≤ BMI ≤ 35 kg/m²
  • •Abdominal obesity
  • •Acceptance to adhere to diet and physical activity recommendations while maintaining global lifestyle habits
  • •Stable body weight (<5% variation) within the last 3 months prior to screening

排除标准

  • •Allergy to nuts and products thereof and allergy to mango fruit
  • •Type I or II diabetes
  • •Severe chronic diseases
  • •History of bariatric surgery and eating disorders
  • •Use of weight management products or medications which could affect nutrients absorption, lipids or carbohydrates metabolism

研究组 & 干预措施

Cashew apple extract (Cashewin)

Active Comparator

干预措施: Cashew apple extract (Cashewin) (Dietary Supplement)

Placebo

Placebo Comparator

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Body weight reduction

时间窗: 12 weeks

次要结局

  • Waist and hip circumferences variation(6 and 12 weeks)
  • Fasting glycemia variation(12 weeks)
  • Fasting insulinemia variation(12 weeks)
  • HOMA-IR index variation(12 weeks)
  • Body weight variation(6 weeks and 12 weeks)
  • Body fat variation(6 and 12 weeks)
  • BMI variation(6 and 12 weeks)
  • Blood lipids (total cholesterol, HDL, LDL, triglycérides) variation(12 weeks)
  • CRPus variation(12 weeks)
  • Variation of glycemia 2h post glucose solution intake(12 weeks)
  • Systolic and diastolic blood pressure variation(6 and 12 weeks)
  • Safety (blood parameters measurements: urea, creatinine, ASAT, ALAT) with adverse events recording(12 weeks)

研究者

发起方
Dialpha
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验